Market Performance
Lupin share price was trading marginally higher at ₹1,946.30 per share on the BSE during Tuesday’s session, following the announcement of a strategic partnership with Switzerland-based Sandoz Group AG.
Main News
Mumbai-headquartered Lupin Ltd has entered into an agreement with Sandoz Group AG to commercialise its biosimilar ranibizumab across multiple global markets.
As per the deal:
- Sandoz will handle the commercialisation of ranibizumab in the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia.
- Lupin will take charge of manufacturing the product and managing regulatory submissions.
In most designated markets, Sandoz will have exclusive marketing rights, except for France, Australia, Vietnam, and Malaysia, where the rights will be semi-exclusive.
Additionally, under a separate agreement, Sandoz will obtain sole rights for commercialisation in Canada, while Lupin will continue to manage manufacturing and regulatory filings.
Company Details
Ranibizumab is a laboratory-engineered, humanized monoclonal antibody fragment designed to bind with vascular endothelial growth factor A and prevent its activity.
It is used in treating:
- Neovascular (Wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Other similar eye-related conditions
Lupin President EMEA and Emerging Markets, Thierry Volle, stated that the collaboration reflects the companies’ commitment to expanding global access to advanced biologic therapies and improving treatment outcomes for underserved patients.
Summary
- Lupin share price moved up to ₹1,946.30 after the announcement.
- Strategic partnership with Sandoz to boost global biosimilar presence.
- Lupin will handle manufacturing and regulatory approvals, while Sandoz will manage market access.
- The biosimilar ranibizumab targets treatments for AMD, RVO, and DME.
Easy & quick
Leave A Comment?